Plain-English translation of NCT05786404 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called PRIM-DJ2727 for people with active ulcerative colitis — an inflammatory bowel disease that causes inflammation and ulcers in the colon. The treatment works by replacing unhealthy gut bacteria with healthy ones from screened donors. Researchers want to see if this approach is safe and whether it helps reduce symptoms and inflammation.
People with ulcerative colitis often have an imbalance in their gut bacteria that may contribute to their disease. This medication represents a new approach to treating the condition by restoring a healthier balance of bacteria in the digestive system, which other studies suggest could reduce inflammation and improve symptoms.
You likely qualify if…
You likely don't qualify if…
If you qualify, you would receive the microbiota treatment either as a frozen preparation delivered through an enema or as capsules taken by mouth. You would attend clinic visits for assessment, blood tests, and stool samples to monitor how your gut bacteria change and whether your symptoms improve. The study involves regular follow-up visits and phone calls to track your progress and safety throughout the treatment period.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
United States